Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aurexis in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus
NCT00198289Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2005
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tefibazumab in Staphylococcus aureus infection, sponsored by Bristol Myers Squibb. Started Apr 2005; status: completed.
02
Drugs
tefibazumab
03
Conditions
Staphylococcus aureus infection
Beyond the preview
Go deeper on NCT00198289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00198289.